Stockscreener 앱 받기
98.66
2.00%
-2.01
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call - Yahoo Finance
Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics? - Yahoo Finance
Halozyme (HALO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance
Is Halozyme Therapeutics (HALO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Stock Forecasts - Yahoo Finance
Wedge Capital Management L L P NC Invests $31.61 Million in Halozyme Therapeutics, Inc. $HALO - marketbeat.com
Handelsbanken Fonder AB Grows Stake in Halozyme Therapeutics, Inc. $HALO - marketbeat.com
Halozyme Therapeutics (NASDAQ:HALO) Sets New 52-Week HighHere's What Happened - marketbeat.com
Halozyme Therapeutics, Inc. (HALO) stock price, news, quote and history - Yahoo Finance Australia
Halozyme director Connaughton sells $167,152 in shares By Investing.com - Investing.com Nigeria
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) Director Sells $167,152.80 in Stock - marketbeat.com
Halozyme director Connaughton sells $167,152 in shares - Investing.com
Halozyme Therapeutics (HALO) affiliate plans stock option-related share sales in Form 144 - Stock Titan
Halozyme Therapeutics (HALO) director sells 1,626 shares in Rule 10b5-1 plan trade - Stock Titan
HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance - Yahoo Finance
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Moderate Buy" by Analysts - marketbeat.com
Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know - Yahoo Finance
Halozyme Therapeutics (HALO) insider schedules 1,626-share stock sale via trading plan - Stock Titan
Halozyme Therapeutics (HALO) Is Up 24.9% After Record Q2, Higher 2026 Guidance And New ENHANZE DealsHas The Bull Case Changed? - Sahm
Biotech Stocks At 52-Week HighsHALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE - RTTNews
Gradient Investments LLC Makes New Investment in Halozyme Therapeutics, Inc. $HALO - marketbeat.com
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Biotech Powerhouse with Robust Revenue Growth and Strong Analyst Support - DirectorsTalk Interviews
HALO Surges As Halozyme Hikes 2026 Guidance And Wins Upgrades - timothysykes.com
Earnings Update: Halozyme Therapeutics, Inc. Beat Earnings And Now Analysts Have New Forecasts For This Year - 富途牛牛
Oliver Luxxe Assets LLC Trims Position in Halozyme Therapeutics, Inc. $HALO - marketbeat.com
Halozyme Therapeutics (HALO) Is Up 24.9% After Raising 2026 Revenue Outlook and Boosting Buybacks - Yahoo Finance
Halozyme Therapeutics (HALO) Stock Looks Expensive At Today’s Price - Sahm
Is Halozyme Therapeutics (HALO) Fairly Valued As Earnings Beat And Guidance Rise? - Yahoo Finance
HALO Surges As Halozyme Lifts 2026 Outlook And Wins Upgrades - timothysykes.com
Halozyme Therapeutics (NASDAQ:HALO) Upgraded to Strong-Buy at Wall Street Zen - marketbeat.com
Assenagon Asset Management S.A. Has $78.09 Million Position in Halozyme Therapeutics, Inc. $HALO - marketbeat.com
Halozyme (HALO) Stock Rallies As Royalties Surge And Guidance Climbs - Sahm
Halozyme Therapeutics Inc (HALO) (Q2 2026) Earnings Call Highlig - GuruFocus
Halozyme Therapeutics Inc (HALO) (Q2 2026) Earnings Call Highlights: Record Revenue and Royalty ... - Yahoo Finance
Halozyme Therapeutics (NASDAQ:HALO) Given New $105.00 Price Target at TD Cowen - marketbeat.com
Halozyme Therapeutics, Inc. Stock 12‑Month Price Target Raised to $99.56, Implies 16% Upside - TradingView
HALO Surges As Halozyme Hikes 2026 EPS And Revenue Outlook - StocksToTrade
Halozyme Therapeutics HALO Surges After Big Earnings Beat And Guidance Hike - StocksToTrade
Halozyme Therapeutics Inc. (HALO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up - Yahoo Finance
Citizens Jmp Raises Halozyme Therapeutics (NASDAQ:HALO) Price Target to $93.00 - MarketBeat
HALOZYME THERAPEUTICS, INC. : LEERINK PARTNERS RAISES TO OUTPERFORM FROM MARKET PERFORM; RAISES TARGET PRICE TO $110 FROM $83 - Bitget
Why Halozyme Therapeutics Is Surging 14.9%: Wells Fargo Maintains Equal-Weight - AlphaStreet
Halozyme Therapeutics (NASDAQ:HALO) Sees Large Volume Increase on Strong Earnings - marketbeat.com
Wells Fargo & Company Boosts Halozyme Therapeutics (NASDAQ:HALO) Price Target to $95.00 - marketbeat.com
Halozyme Therapeutics (NASDAQ:HALO) Upgraded to "Outperform" at Leerink Partners - MarketBeat
Halozyme Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $115.00 - marketbeat.com
Halozyme Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:HALO) 2026-08-07 - Seeking Alpha
Morgan Stanley Adjusts PT on Halozyme Therapeutics to $105 From $93, Maintains Overweight Rating - marketscreener.com
Halozyme Therapeutics (NASDAQ:HALO) Issues Quarterly Earnings Results, Beats Expectations By $0.49 EPS - MarketBeat
Halozyme Therapeutics Q2 Earnings Call Highlights - marketbeat.com
Is Halozyme Therapeutics (HALO) Undervalued After Q2 Earnings Be - GuruFocus
Halozyme Therapeutics stock hits all-time high at 84.49 USD By Investing.com - Investing.com Nigeria
Halozyme Therapeutics (NASDAQ:HALO) Releases FY 2026 Earnings Guidance - marketbeat.com
Halozyme Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
(HALO) Halozyme Therapeutics Now Expects 2026 Adjusted EPS Range $8.65-$9.00, vs. FactSet Est of $7.94 - marketscreener.com
(HALO) Halozyme Therapeutics Now Expects 2026 Revenue Range $1.835B-$1.910B, vs. FactSet Est of $1.77B - marketscreener.com
Halozyme Therapeutics (NASDAQ:HALO) Beats Expectations in Strong Q2 CY2026, Guides for Strong Full-Year Sales - Yahoo Finance
Halozyme Therapeutics Q2 Adjusted Earnings, Revenue Rise; Shares Gain After Hours - marketscreener.com
HALOZYME THERAPEUTICS, INC. 2026: Revenue $481M, EPS $1.9— 10-Q Summary - TradingView
HALOZYME THERAPEUTICS ($HALO) Releases Q2 2026 Earnings, Stock Rises - Quiver Quantitative
Halozyme Therapeutics Inc. R (RV7.DU) Q2 FY2026 earnings call transcript - Yahoo Finance
Halozyme Q2 2026 results: Royalty revenue rises 50% as guidance increases - TradingKey
Form 10-Q HALOZYME THERAPEUTICS, For: Jun 30 - StreetInsider
Halozyme Therapeutics (NASDAQ: HALO) posts $481M Q2 2026 revenue - Stock Titan
Halozyme Therapeutics: Q2 Earnings Snapshot - Barchart.com
0.52%
0.07%
자본화:
|
볼륨(24시간):